evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

56 questions · 57 findings · 5 reviews · Schizophrenia

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 6 · 10.5%GRADE not reported 13 · 22.8%Very low 22 · 38.6%Low 13 · 22.8%Moderate 3 · 5.3%High 0 · 0%

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Physiological measures: 1c. Average fasting glucose change ‐ switching to aripiprazole and quetiapine · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Adverse events: 1a. Serious adverse event ‐ switching to aripiprazole · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in adverse events: 1a. Serious adverse event ‐ switching to aripiprazole compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT‐medium term (3‐12 months)

Global state: Changing dose because of deterioration ‐ switching to haloperidol decanoate from fluphenazine decanoate · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in global state: Changing dose because of deterioration ‐ switching to… compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT‐medium term (3‐12 months)

Mental state: Deteriorated ‐ switching to haloperidol decanoate from fluphenazine decanoate · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in mental state: Deteriorated ‐ switching to haloperidol decanoate from… compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Weight (kg) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
2 findings from 1 review

Switch to a specific antipsychotic vs switch to a different specific antipsychotic

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Weight: 2a. BMI ‐ Increase · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes weight: 2a. BMI ‐ Increase compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Relapse · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in global state: Relapse compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Satisfaction with care: Loss to · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes satisfaction with care: Loss to compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).

1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT‐medium term (3‐12 months)

Weight: BMI not improved · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT‐medium term (3‐12 months)

Physiological measure: Metabolic syndrome · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT‐medium term (3‐12 months)

Adverse effects: serious · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT‐medium term (3‐12 months)

Satisfaction with care: Loss to · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes satisfaction with care: Loss to compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (very low certainty).

1 finding from 1 review